Bolder Biotechnology, Inc.

Amgen Inc.

Dsm IP Assets B.v.

Monsanto Company

Seikagaku Corporation

Getty Scientific Development Company

Other

William Marsh Rice University

Martek Biosciences Corporation

Cp Kelco U.s., Inc.

Baxter Biotech Technology Sarl

Daniel H Doherty

George N Cox

Leu-Fen H Lin

Franklin D Collins

Jack Lile

Susan Bektesh

Craig A Weaver

Mary S Rosendahl

Rebecca W Vanderslice

James George Metz

Ross E Zirkle

Randal A Hassler

John D Marrelli

Antony James Mathews

Kentaro Miyamoto

John S Olson

Toshikazu Minamisawa

Christopher B Glascock

Douglas D Lemon

Michael J Weickert

Donna M Ferber

Michael Betlach

Michael A Capage

Michael R Betlach

The invention relates to the field of recombinant DNA technology for the production of chondroitin, including the production of chondroitin sulfate via a combination of recombinant bacterial fermentation and post-fermentation sulfation.

Compositions and methods for bacterial and genetically modified microorganism production of chondroitin

The present invention relates to novel methods for making and refolding insoluble or aggregated proteins having free cysteines in which a host cell expressing the protein is exposed to a cysteine blocking agent. The soluble, refolded proteins produced by the novel methods can then be modified to increase their effectiveness. Such modifications include attaching a PEG moiety to form PEGylated proteins.

Method for preparing recombinant granulocyte colony stimulating factor cysteine muteins

Disclosed are chimeric polyunsaturated fatty acid (PUFA) olyketide synthase (PKS) proteins and chimeric PUFA PKS systems, including chimeric PUFA PKS proteins and systems derived fromand. Disclosed are nucleic acids and proteins encoding such chimeric PUFA PKS proteins and systems, genetically modified organisms comprising such chimeric PUFA PKS proteins and systems, and methods of making and using such chimeric PUFA PKS proteins and systems.

Chimeric PUFA polyketide synthase systems and uses thereof

Compositions and methods for bacterial production of chondroitin

Disclosed are chimeric polyunsaturated fatty acid (PUFA) polyketide synthase (PKS) proteins and chimeric PUFA PKS systems, including chimeric PUFA PKS proteins and systems derived fromand. Disclosed are nucleic acids and proteins encoding such chimeric PUFA PKS proteins and systems, genetically modified organisms comprising such chimeric PUFA PKS proteins and systems, and methods of making and using such chimeric PUFA PKS proteins and systems.

The present invention relates to novel methods of making soluble proteins having free cysteines in which a host cell is exposed to a cysteine blocking agent. The soluble proteins produced by the methods can then be modified to increase their effectiveness. Such modifications include attaching a PEG moiety to form pegylated proteins.

Methods for making proteins containing free cysteine residues

The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby. Also disclosed are therapeutic methods for using the cysteine variants of the invention.

Method of preparing cysteine mutants of human recombinant GM-CSF

In vivo stimulation of peripheral blood progenitor cells by granulocyte-macrophage colony stimulating factor (GM-CSF) cysteine muteins and their PEGylated variants

The present invention relates to novel methods for making fusion proteins comprising a cytokine or growth factor fused to an immunoglobulin domain. The growth factor/cytokine can be fused directly to an immunoglobulin domain or through a peptide linker. The purified growth factor/cytokine-IgG fusion proteins produced by the novel methods are biologically active and can be used to treat diseases for which the non-fused growth factor/cytokine are useful.

Immunoglobulin fusion proteins

Method for refolding proteins containing free cysteine residues

A novel neurotrophic factor referred to as glial cell line-derived neurotrophic factor (GDNF) has been identified and isolated from serum free growth conditioned medium of B49 glioblastoma cells. Rat and human genes encoding GDNF have been cloned and sequenced. A gene encoding GDNF has been subcloned into a vector, and the vector has been used to transform a host cell in order to produce biologically active GDNF in a recombinant DNA process.

Nucleic acids encoding glial cell line-derived neurotrophic factor (GDNF)

Derivatives of growth hormone and related proteins, and methods of use thereof

The invention relates to novel recombinant hemoglobins having reduced nitric oxide scavenging and/or increased high soluble expression. The invention further relates to methods of increasing the soluble expression of recombinant hemoglobin by adding exogenous hemin in molar excess of the heme binding sites of recombinant hemoglobin.

Hemoglobin mutants with increased soluble expression and/or reduced nitric oxide scavenging

Growing community of inventors

Boulder, CO, United States of America

Daniel H Doherty